Table 5.
Summary comparing data of five clinical trials and a cohort in Joinville/Brazil (JOINVASC IA).
| Study N IAT/IVT |
NIHSS range |
IV rt-PA | TICI 2B/3 |
LSN to groin (mdn) |
mRS 0–2 at 90 days |
sICH |
Device complications | Mortality |
||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IVT | IAT | IVT | IAT | IVT | IAT | IVT | IAT | |||||
| MR CLEAN 500 233/267 |
18 (14–21) |
17 (14–22) |
90% | 59% | 200 | 29% | 53% | 2.7% | 3.6% | Embol. 13 | 22% | 21% |
| EXTENDED IA 70 35/35 |
17 (12–20) |
16 (13–20) |
76% | 72% | 200 | 29% | 53% | 2.7% | 3.6% | Perf.1 | 19% | 10% |
| ESCAPE 315 165/150 |
13 (9–19) |
17 (13–20) |
100% | 86% | 210 | 40% | 71% | 6% | 0% | Perf.1 Embol.2 |
20% | 9% |
| SWIFT PRIME 196 98/98 |
17 (13–19) |
17 (13–20) |
98% | 88% | 224 | 36% | 60% | 3% | 0% | SAH 4 | 12% | 9% |
| REVASCAT 206 103/103 |
17 (12–19) |
17 (14–20) |
73% | 66% | 269 | 28% | 44% | 1.9% | 1.9% | Perf.5 Embol.5 |
16% | 18% |
| JOINVASC IA 113 31/82 |
16 (14–21) |
19 (17–24) |
81% | 71% | 217 | 37% | 55% | 12% | 10% | Perf.1 | 39% | 26% |
NIHSS indicates baseline National Institute of Neurological Disorders and Stroke Scale; rt-PA: recombinant tissue-type plasminogen activator; TICI 2b/3: patients in IAT group achieving thrombolysis in cerebral infarction grade 2b or 3 reperfusion according to Thrombolysis in Cerebral Infarction Score. LSN: last time seen normal to groin puncture; mRS: functional independence at modified Rankin scale; sICH: symptomatic intracerebral hemorrhage after IVT or IAT; Embol. Catheter embolization; Perf. Vessel perforation.